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Background: To review the descriptive epidemiological data on neuronal ceroid lipofuscinoses (NCLs) in Italy,
identify the spectrum of mutations in the causative genes, and analyze possible genotype-phenotype relations.
Methods: A cohort of NCL patients was recruited through CLNet, a nationwide network of child neurology units.
Diagnosis was based on clinical and pathological criteria following ultrastructural investigation of peripheral tissues.
Molecular confirmation was obtained during the diagnostic procedure or, when possible, retrospectively.
Results: One hundred eighty-three NCL patients from 156 families were recruited between 1966 and 2010; 124 of
these patients (from 88 families) were tested for known NCL genes, with 9.7% of the patients in this sample having
not a genetic diagnosis. Late infantile onset NCL (LINCL) accounted for 75.8% of molecularly confirmed cases, the
most frequent form being secondary to mutations in CLN2 (23.5%). Juvenile onset NCL patients accounted for
17.7% of this cohort, a smaller proportion than found in other European countries. Gene mutations predicted
severe protein alterations in 65.5% of the CLN2 and 78.6% of the CLN7 cases. An incidence rate of 0.98/100,000 live
births was found in 69 NCL patients born between 1992 and 2004, predicting 5 new cases a year. Prevalence was
1.2/1,000,000.
Conclusions: Descriptive epidemiology data indicate a lower incidence of NCLs in Italy as compared to other
European countries. A relatively high number of private mutations affecting all NCL genes might explain the
genetic heterogeneity. Specific gene mutations were associated with severe clinical courses in selected NCL forms
only.
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The neuronal ceroid lipofuscinoses (NCLs) are the most
common group of inherited, progressive neurodegenera-
tive diseases of childhood, which are secondary to ab-
normal intralysosomal storage of autofluorescent material
and show specific ultrastructural features. In the vast ma-
jority of patients, onset occurs in the pre-school years and
is characterized by a combination of visual impairment,
cerebellar ataxia, and signs and symptoms of diffuse* Correspondence: alessandro.simonati@univr.it
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reproduction in any medium, provided the ortelencephalic involvement, such as seizures, behavioral
disturbances, and cognitive deterioration. The disease
leads to progressive degeneration of cortical and cerebellar
structures with secondary fiber tract atrophy. The out-
come is always fatal; death occurs within a few years of
the disease onset, in early adulthood, or even during the
third or fourth decade of life, depending on the phenotype
[1]. A clinical diagnosis is supported by ultrastructural evi-
dence of abnormally shaped cytosomes in peripheral
blood or skin biopsy [2].
The NCLs are inherited as autosomal recessive traits, al-
though a rare, autosomal dominant adult-onset form has
been identified [3]. The disease shows broad clinical and
allelic heterogeneity; age at onset and, more recently, gen-
etic characterizations have led to the development of aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Analytical data of the cohort of patients
according to clinical NCL classification
NCL Form Patients (# cases;%) Families Molecular Investigations
INCL 10 (5.5) 7 8
LINCL* 124 (67.7) 109 94
JNCL** 49 (26.8) 40 22
Total 183 156 124
* including so-termed variant (*) and protracted forms (**).
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rithms [4,5]. To date, fewer than 400 mutations in 12
human genes have been entered in the NCL database [6].
Nonetheless, approximately 10% of all patients do not
have any of the known genetic forms of NCL and further
heterogeneity is thus anticipated.
Information on the actual incidence and prevalence of
childhood NCL is based mainly on data gathered from
clinical and morphological studies conducted in the pre-
genetic era [7-13]. Over the past 10 years, routine use of
molecular genetics to corroborate clinical diagnoses has
made it possible to obtain more accurate epidemiological
data on the NCLs, which have been shown to have a
worldwide distribution [14]. Moreover, some studies seem
to indicate a higher-than-expected incidence in specific
geographical regions [15,16]. In this study, we investigated
the frequency of childhood-onset NCLs in Italy, examin-
ing clinical and molecular data collected mainly through a
collaborative network (CLNet) of paediatric neurology
units applying common diagnostic protocols.
Patients and methods
The study included a large cohort of children born be-
tween 1966 and 2010. The data on all but five of these
children were collected through CLNet; the remaining
five were patients investigated by institutions not belong-
ing to the network, but whose clinical data were available
from the literature and from medical records [17,18]
(S. Berkovic, personal communication). Diagnosis of NCL
was based on clinical evaluation, neurophysiological inves-
tigations (EEG, multiple evoked potentials), neuroradiolo-
gical findings, biochemical assays (when available), and
ultrastructural analysis of blood lymphocytes and/or skin
biopsies. Blood samples were obtained for DNA analysis
in about 75% of the cohort. Molecular investigations of
the CLN1-3, CLN5-8 and CLN10 genes in peripheral
blood DNA and the rapid detection of the common
1.02Kb deletion of CLN3 were performed using previously
described procedures [19-25]. ATP13A2 and KCTD7 (re-
cently reported to be mutated in CLN12 [26] and CLN14
[27], respectively) were not analyzed.
Descriptive epidemiological studies were conducted
with reference to a 13-year period: 1992–2004. Demo-
graphic data for incidence and prevalence analyses were
obtained from the Italian National Institute of Statistics
(www.demo.istat.it). Cumulative NCL incidence was eval-
uated as described elsewhere [7]. Genotype data were used
for molecular analysis as well as for genotype-phenotype
correlations. The type and location of specific mutations
were compared to the disease phenotypes as defined in
the CLNet clinical database to establish their severity and
identify possible population-specific variants. In addition,
we correlated clinical diagnoses in Italian patients with
frequency and severity of individual mutations.Investigations were performed following signed, informed
consent by childrens’ parents (or caregivers) according to




One hundred eighty-three patients with childhood-onset
NCL, born between 1966 and 2010 and belonging to
156 families were identified in the CLNet database. The
sample comprised 81 boys, 66 girls, and 36 patients
whose gender could not be ascertained because the ac-
cess codes were not available. The investigated cohort
includes patients reported in an earlier study [8]. Gen-
eral study population data are summarized in Table 1.
There emerged no characteristic pattern of distribution
of the patients with NCLs across the country, and the
small geographical clusters that did emerge were related
to familial cases. Thirty children (16.4%) were not of
Italian ancestry, being either born in Italy to foreign par-
ents, or adopted from abroad. Fourteen of these children
originated from the Balkans, three from Eastern Europe,
nine from Middle Eastern countries, and one each from
Saharan Africa, India, Sri Lanka, and Nepal.
According to the clinical diagnosis of the all cohort
(including patients whose diagnosis was not ascertained
molecularly, but by neurophysiological data and ultra-
structural findings), Late Infantile NCL (LINCL) was the
most frequent subtype, affecting 67.7% of the patients.
Infantile NCL (INCL) and Juvenile NCL (JNCL, includ-
ing the so-called protracted form) accounted for 5.5%
and 26.8%, respectively (see Table 1).
One hundred twenty-four patients were tested for
mutations in the known NCL genes, and a molecular
diagnosis was obtained in 112 of them (90.3%); the other
twelve cases remained undiagnosed (Table 2). The clin-
ical and ultrastructural findings of the 59 patients not
undergoing DNA analyses were consistent with: INCL
(n=2), LINCL (n=29), and JNCL (n=28).
The mutations found in this cohort were scattered
among all the examined NCL genes, none of which
appeared to be overrepresented. CLN2 mutations
accounted for about 24% of the cases, all showing the
LINCL phenotype. Mutations in CLN6 were present in
Table 2 Molecular findings in 124 NCL patients according
to both clinical form and mutated gene
GENE INCL LINCL JNCL Total (%)
CLN1 6 9 2 17 (13.7)
CLN2 0 29 0 29 (23.5)
CLN3 0 0 16 16 (12.9)
CLN5 0 7 0 7 (5.6)
CLN6 0 18 3 21 (16.9)
CLN7 0 14 0 14 (11.3)
CLN8 0 7 0 7 (5.6)
CLN10 0 1 0 1 (0.8)
CLNX 2 9 1 12 (9.7)
Total (%) 8 (6.5) 94 (75.8) 22 (17.7) 124
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cluding LINCL (18 cases) and JNCL (3 cases). Lower
mutation rates were observed for CLN1, CLN3 and
CLN7. Three phenotypes were observed in association
with mutations in CLN1, the LINCL one being the most
common [28]. In accordance with figures published in a
pre-DNA study [8], the number of CLN3-mutated
patients was relatively low, accounting for 12.9% of the
molecularly investigated cases. Even lower frequencies
of CLN5, CLN8 and CLN10 mutations were observed.
CLN8 was the only gene not associated with familial
cases, even though instances of parental consanguinity
were rare and only a few of the kindred had multiple
affected sibs.
Twelve cases, whose clinical and ultrastructural fea-
tures were consistent with a diagnosis of NCL, remained
undiagnosed, even after screening of NCL genes. Eight
of them, from three families, were not of Italian origin
(two from the Balkans and one from Sri Lanka).
For the purpose of conducting an incidence analysis,
the 69 patients (from 59 families; 38 boys and 31 girls)
born between 1992 and 2004 were matched with the
total number of live births recorded in the same period
in Italy: this gave an overall NCL incidence, in Italy, of
0.98/100,000 (that is, 1 in 102,041), predicting five new
cases a year. A genetic diagnosis was obtained in 66 of
these children (95.7%): 48 harboured mutations in genes
associated with LINCL, which thus accounted for 69.6%
of the cases. Only six patients with mutations in CLN3
were born during the incidence study period (corre-
sponding to 8.7% of this group), a figure which is in ac-
cordance with the low frequency of CLN3 mutations in
Italy (see Table 2).
In mid-January 2005, 72 out of 183 NCL patients were
still alive, giving a prevalence rate of 1.2/1,000,000. Plot-
ting the cumulative index of 183 patients against year of
birth resulted in a double S-shaped curve; the curve
showed a slight deflection corresponding to lower annualoccurrence of NCL cases over one decade (late 1980s to
late 1990s). The flattened curve corresponding to the most
recent years may be related to cases reported to CLNet
Units but still awaiting diagnosis (Figure 1).
Molecular data analysis
A total of 77 mutations were detected after examining 8
genes (see Additional file 1). Of the 112 children with
molecular confirmation, 17 carried mutations in CLN1,
in association with three phenotypes: INCL (n= 6),
LINCL (n= 9) and JNCL (n= 2). Eleven different muta-
tions were identified; four missense and seven predicting
either truncated or severely affected protein. Five of the
children with INCL carried either homozygous or com-
pound heterozygous severe mutations, with 9/10 alleles
predicting early protein truncation. The other harboured
a homozygous missense mutation (c.722C>T/p.S241L),
which might predict a less severe clinical course, not-
withstanding the early onset. Of the nine patients with
LINCL, six carried homozygous missense mutations
(c.665 T>C/p.L222P being the most frequent), two were
homozygous for an insertion leading to aberrant spli-
cing, and the last was compound heterozygous for two
nonsense variants [28]. Interestingly, the 3.6 Kb large de-
letion c.124+1214_235-102del was associated with a se-
vere infantile form (with fatal outcome at age 6 years),
when allelic to a nonsense mutation, whereas it gave ori-
gin to a less severe phenotype (still alive at 16 years)
when in combination with a nucleotide change leading
to a missense mutation. Two sibs, heterozygous for c.363-
3 T>C, which predicts aberrant splicing, and c.541 G>A/
p.V181M, showed a JNCL phenotype. The c.665 T>G/p.
L222P mutation was the most frequent in the CLN1
patients, being detected in 29.4% of alleles.
The patients with mutations in CLN2 were clinically
homogeneous, all 29 presenting manifestations consistent
with a LINCL phenotype. Seventeen different mutations
were detected. Six were missense mutations predicting
aminoacid changes. Five mutations were frameshifts or
splice site variants, and six were nonsense mutations.
The c.622C>T/p.R208* nonsense variant accounted for
20% of CLN2 alleles. Altogether, molecular investigations
of CLN2 predicted a severely altered gene product in
65.5% of cases.
The classical juvenile phenotype was present in all the
patients mutated in CLN3. Twelve patients carried the
homozygous 1.02 Kb deletion, whereas one was a het-
erozygous compound. Two different homozygous non-
sense mutations were detected in the remaining three
patients. It is worth noting that none of the children of
non-Italian ancestry was mutated in CLN3.
Forty-six LINCL children were found to have muta-
tions in the CLN5-CLN6-CLN7-CLN8 genes. A high rate
of different mutations (as compared to number of alleles
Figure 1 Plotting of cumulative index of 183 NCL cases born in 1966–2010 as ascertained by CLNet. Patients are sorted by year of birth
and plotted by number of new cases per year (dark dots) and cumulative number of cases. The curve shows relatively steady recruitment of new
cases over time, with a slight deflection from the mid-1980s to the mid-1990’s (circled). The flat ends of the curve are possibly related to under-
diagnosis during the late-1960s to early-1970s, and the presence of still undiagnosed cases today (right end of the curve).
Table 3 Genetic heterogeneity expressed as the number
of mutations per examined gene in 124 NCL patients
GENE Patients Alleles Mutations
CLN1 17 34 11
CLN2 29 56 17
CLN3 16 32 3
CLN5 7 14 7
CLN6 21 42 17
CLN7 14 28 14
CLN8 7 14 7
CLN10 1 2 1
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marked genetic heterogeneity. Missense and nonsense
mutations were evenly distributed in all the forms, ex-
cept for CLN8, which showed a prevalence of missense
mutations. In CLN5 the c.772 T>G/p.Y258D mutation
accounted for 1/3 of the alleles. Seventeen different
disease-related variants were detected in the 21 patients
carrying mutations in CLN6. Eleven were nucleotide
changes that predicted an amino acid substitution, while
three were frameshift and three nonsense mutations. Se-
vere protein alterations were predicted in 10 cases. The
mutations were evenly distributed, the most frequent
being c.896C>T/p.P299L and c.662A>G/p.Y221C, to-
gether affecting a total of 10 alleles. No genotype-
phenotype correlation could be drawn for this form. In
CLN7, eight out of the 14 mutations were either splice
site/frameshift variants or nonsense changes leading to
an early stop codon. Severe protein alterations were
predicted in 79% of cases. Mutations in CLN8 were
detected in seven patients: five nucleotide substitutions
and two deletions. Finally, a single missense in CLN10
was detected in one child. Once again, the genotype did
not seem to predict the phenotype.Findings showing the genetic heterogeneity of the co-
hort are summarized in Table 3.
Discussion
In this study, we investigated the relative incidence of
childhood forms of NCL in Italy and the phenotypic
spectrum related to mutations in known NCL genes. De-
scriptive epidemiology data, collected through the appli-
cation of shared clinical and morphological diagnostic
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genes, revealed an incidence rate of 0.98/100,000 live
births in the period 1992–2004. This figure is 58%
higher than that recorded in the pre-genetic era [8], and
the increase is probably due to the availability of new
diagnostic procedures, such as biochemical and molecu-
lar testing, and greater awareness of the disease. The
number of new NCL cases has been increasing con-
stantly since the mid-1970s (Figure 1), as shown by
steady rise in the cumulative index, which predicts about
five new cases a year. Even though the years included in
our incidence analysis belong to the molecular era, the
incidence rate of NCLs in Italy was still found to be
lower than in other European countries where epidemio-
logical investigations were recently performed [16,29]. It
is unclear whether this is due to an ascertainment bias,
since our study might have missed cases presenting in
late childhood/adolescence and not referred to neurope-
diatric centers (e.g., JNCL patients with visual problems
or psychiatric manifestations alone might have escaped
our registry survey) or to misdiagnosed cases. Further-
more, we may have missed a small number of cases
diagnosed elsewhere before molecular analysis tools be-
came available in Italy. Indeed, between the late 1980s
and the late 1990s there appeared to be fewer children
born with NCL (Figure 1), and this may be because
some Italian patients recorded in the NCL mutation
database [6] or reported in the literature [25,30,31] were
not subsequently included in the CLNet database. This
discrepancy might also be explained by the still limited
proportion (16%) of cases, in the CLNet database, occur-
ring in non-Italian ethnicities. In this regard, Italy differs
from other European countries, such as United Kingdom,
the Netherlands, and Germany, where higher levels of
immigration from the Middle East, Asia and countries
with high rates of inbreeding result in a much broader
ethic mix of NCL patients.
All the known NCL forms and variants represented in
the CLNet database were evenly distributed (see Table 2).
LINCL appear to be the most frequent forms, account-
ing for an incidence of 0.78/100,000 live births. About
half of the cohort had a genetic diagnosis of LINCL, the
single most affected gene being CLN2, found to be
mutated in 23.5% of the entire sample. High frequencies
of LINCL and CLN2 mutations have been reported in
only two previous studies, carried out in restricted
geographic areas, namely British Columbia [32] and
Newfoundland [15], respectively. In the latter study,
LINCL patients mutated in CLN5 and CLN6 accounted
for 26% of the whole LINCL population.
Nearly 17% of patients of this cohort were mutated in
CLN6. Two phenotypes were identified: a subtype char-
acterized by late infantile onset and survival into the sec-
ond decade, and a late juvenile/adolescent form with adisease course protracted into adulthood. Three clinical
variants of CLN1 mutations were identified, and pheno-
typic expression was apparently unrelated to the kind of
mutation (and the predicted effects on the gene
product). Relatively few children in our sample were
affected by INCL, a result which is at odds with the pat-
tern in countries such as Finland where a founder effect
has been recognized [33]. The frequency of CLN3-
mutated patients was also relatively low compared with
the worldwide incidence rates, and also considering the
allegedly frequent occurrence of mutations in CLN3 in
Northern Europe. The apparent discrepancy in our study
between the numbers of clinical diagnoses and of con-
firmatory molecular tests (see Table 1 and Table 2) might
be due to the fact that before testing was possible in our
country all genetic analyses were made abroad. The distri-
bution of Italian JNCL cases by year of birth differs from
that other NCL forms, failing to show significant differ-
ences between the pre- and post-molecular era. Con-
versely, there was a surge in LINCL diagnoses once
molecular testing became available. Prospective studies will
probably better indicate the rate of relative frequencies for
juvenile NCL forms.
As expected, given the heterogeneity of the clinical
spectrum of childhood NCL as a whole, we did not
observe clear-cut phenotype-genotype relationships. How-
ever, in INCL and LINCL secondary to mutated CLN2 —
the most severe forms in terms of signs/symptoms at
onset, disease progression and survival — the majority of
mutations predicted severe loss of function. Similarly,
CLN7 showed a high frequency of mutations expected to
result in markedly abnormal gene product expression
(78.6%). Accordingly, a mutation in CLN7 was a bad pre-
dictor of clinical severity among the LINCL cases in our
cohort. Only one child in this cohort harbored a CLN10
mutation, underlining the rarity of this condition [34].
As shown elsewhere [35-37], about 10% of the NCL
cases in this survey remained without a genetic diagno-
sis. Therefore, new NCL genes need to be identified, and
the availability of informative families will help in accom-
plishing this. However, we cannot rule out that some of
the CLNX patients of this cohort might display mutations
in either ATP13A2 or KCTD7, even if their phenotypes
are markedly different form the reported cases [26,27].
With the exception of the CLN3 form, NCL in Italy
seems to be characterized by heterogeneity, both clinical
(phenotypes) and genetic (number of mutations/genes).
The finding of a high number of private mutations with-
out geographic clusters and the lack of large families
with multiple affected children suggests that Italian NCL
cases have an assorted genetic background. This variabil-
ity might reflect the fact that Italy, a country lying on
migratory routes and with a relatively low rate of inbreed-
ing, has historically known several different dominations,
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invaders.
The enhanced knowledge of the epidemiology of NCL in
Italy, particularly the figures of prevalence and the predic-
tion of new cases per year, together with increase know-
ledge of the long term complications of the disease(s)
should help a better allocation of health resources for plan-
ning sufficient care in children and their families. It will
also help to increase the awareness about this group of dis-
eases, possibly shortening the time lag between onset and
the definite diagnosis.
Conclusions
In the period 1992–2004 the incidence of NCLs in Italy
was 0.98/100,000 live births, a rate higher than would
have been expected in the “pre-DNA” era but relatively
lower than what is observed in other European coun-
tries. With Italy now seeing increasing rates of immigra-
tion of highly consanguineous populations from North
African countries and Eastern Europe, it is tempting to
hypothesize that these figures will change again in future
investigations.
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